Form 8-K - Current report:
SEC Accession No. 0001725160-25-000104
Filing Date
2025-05-14
Accepted
2025-05-14 16:09:35
Documents
16
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20250514.htm   iXBRL 8-K 33544
2 EX-99.1 zntl_q12025earningspr.htm EX-99.1 65609
7 zenalis_primarybluenavya.jpg GRAPHIC 68307
  Complete submission text file 0001725160-25-000104.txt   344648

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20250514.xsd EX-101.SCH 2039
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20250514_def.xml EX-101.DEF 4069
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20250514_lab.xml EX-101.LAB 27067
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20250514_pre.xml EX-101.PRE 16301
18 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20250514_htm.xml XML 2835
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 25945521
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)